Educational research only—not investment advice or a recommendation. Scores and estimates may use delayed, incomplete, restated, or corrected market and filing data. Independently verify information before making an investment decision.

MBody AI Ltd.

MBAINASDAQ
Wall Street ScoreUnder review
$2.04USD+$0.24 (+13.61%)

The research record contains a warning or limitation that requires review before a complete Wall Street Score can be published. Available company and financial research remain accessible.

Company website mbody.ai
Headquarters7111 Syntex Drive, Mississauga, ON, L5N 8C3, CA
Financial statement currencyUSD · no FX conversion applied
Healthcare · Biotechnology
Price from Oct 29, 2026Financials updated Oct 23, 2026

MBAI · Price history

Price at last available close

$2.05

−$1.70 (-45.33%) 1M

2026-10-28

Tap or drag sideways to inspect a price. Use two fingers to compare automatically. Release to scroll. Use Shift + arrow keys to compare with a keyboard.

Company & revenue

About MBody AI Ltd.

Primary reporting period: 2025-12-31 · Research updated Oct 13, 2026. A research update is not a new financial filing.

Who they are

MBody AI Ltd. designs and develops embodied artificial intelligence software for autonomous workforce and operational automation. The company's platform provides Perception AI for computer vision and environmental understanding, Cognitive AI for adaptive decision-making, and Learning AI for continuous on-site machine learning. Its platform also provides dynamic task and route optimization, along with fleet intelligence and coordination across multi-unit operations.

How they make money

MBody AI generates revenue through its hardware-agnostic MBody AI Orchestrator platform, which integrates and coordinates diverse robotic and sensor-based systems for enterprise clients. The company provides this AI infrastructure to enable autonomous workforce operations, charging for platform deployment and ongoing orchestration services across sectors including hospitality, healthcare, logistics, and data centers.

Products & services

MBody AI Orchestrator, a hardware-agnostic enterprise-scale AI platform that integrates and coordinates robotic and intelligent devices from various manufacturers.

Brands & revenue mix

MBody AI Orchestrator

The company's primary proprietary AI platform for robotic and sensor-based system integration.

Separate brand revenue is not available in this research.Source

Revenue share is not unit sales or a best-seller ranking. Parent brands and included sub-brands can overlap; do not add overlapping rows.

Product / operating segments

No reconciled product or operating-segment revenue breakdown is available for the current research period. Company-wide revenue remains separate from segment disclosure.

Geographic revenue

No reconciled geographic revenue breakdown was confirmed for the current research period.

Customer types

Customer concentration

No quantified customer-concentration disclosure is available in the current saved research.

Suppliers, materials & equipment

No supplier relationships were confirmed in the sources reviewed. This does not mean the company has no suppliers.

Business relationships & partnerships

  • Check-Cap Ltd. — A strategic merger agreement completed on August 26, 2026, where MBody AI became a wholly-owned subsidiary of Check-Cap Ltd.Source
  • ARC Group International Inc. — Provider of an equity line of credit facility to support the company's financial operations.Source

Strengths

  • Hardware-agnostic AI platform architectureSource
  • Proven enterprise-scale deploymentsSource

Risks

  • Operational risks associated with scaling commercial deploymentsSource
  • Dependence on successful integration of merger activitiesSource

Company-specific research

Questions worth answering for MBAI

Research inputs 73% complete

These questions are generated from this company's current financial and score data so the page adds context instead of treating the headline score as a stand-alone conclusion.

  • •How long can MBAI fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • •Is MBAI's debt load manageable relative to cash generation, interest costs and upcoming maturities?
  • •What future growth or profitability would be needed to justify MBAI's current valuation?
  • •What does the current missing revenue history warning mean for the reliability or interpretation of MBAI's score?
⚠ 6 warningsView warning details
Debt service riskM&A headline · Sep 16, 2026M&A headline · Aug 28, 2026Reverse-split headline · Aug 13, 2026Reverse-split headline · Aug 11, 2026+1 more
Business analysis: 16 days ago · Fresh

Essential Investment Snapshot

Market Cap

$2.1M

P/E Ratio

0.4

EPS

$4.62

52-Week High

$27.44

52-Week Low

$2.02

Beta

0.80

Analyst Target

$10.00

Shares Outstanding

890K

Total Debt

$16K

Dividend

No current dividend

View dividend history

Liquidation Value / Share

$3.86

Estimated net asset value per share

Momentum & Volatility Signals

Two different market-behavior signals. Momentum measures direction and trend strength. Volatility measures how large and unstable the price moves are, regardless of direction.

0–100 market signals
Momentum
4/ 100
+3 pts / 5d

Strong downward momentum

5D -6.8% · 20D -42.1% · RSI 31 · Price vs 20D avg -24.5%
Volatility
91/ 100
-1 pts / 5d

Extreme movement

20D realized vol 127.7% · 60D 109.8% · Acceleration 1.16x
Momentum = Where is it going?

A high momentum score means price has been trending upward with confirming short- and medium-term strength. A low score means downward or weakening momentum.

Volatility = How violently is it moving?

A high volatility score means larger, less stable price swings. It can happen while a stock is rising or falling, so high volatility is not automatically bullish or bearish.

Important: the volatility score above is based on realized price volatility. Implied volatility (IV) comes from options prices and represents the market's expected future movement. Wall Street Score will keep IV separate and will only display it when a verified options-chain feed is available.

Notices for MBAI

Detected from reported data — verify before acting.

Debt service risk

Interest coverage is low (~-12.8x). Earnings may be strained to cover interest expense.

M&A headline · Sep 16, 2026

MBody AI Completes Name Change Following Merger and $10 Million Offering — This is a provider-linked headline, not an independently confirmed event. Check the article and company filings for the subject, proposed/completed status, and subsequent updates.

GlobeNewsWire

M&A headline · Aug 28, 2026

Check-Cap Completes MBody AI Merger, Closes $10 Million Underwritten Offering — This is a provider-linked headline, not an independently confirmed event. Check the article and company filings for the subject, proposed/completed status, and subsequent updates.

GlobeNewsWire

Reverse-split headline · Aug 13, 2026

Check-Cap (MBAI) Advances Merger with MBody AI; Reverse Share Split Effective — This is a provider-linked headline, not an independently confirmed event. Check the article and company filings for the subject, proposed/completed status, and subsequent updates.

GlobeNewsWire

Reverse-split headline · Aug 11, 2026

Check-Cap Advances MBody AI Merger; Reverse Share Split — This is a provider-linked headline, not an independently confirmed event. Check the article and company filings for the subject, proposed/completed status, and subsequent updates.

GlobeNewsWire

Reverse-split headline · Aug 7, 2026

Check-Cap Announces Reverse Share Split — This is a provider-linked headline, not an independently confirmed event. Check the article and company filings for the subject, proposed/completed status, and subsequent updates.

GlobeNewsWire

Community Sentiment

0 active · 0 total calls
0% Bullish (0) 0% Bearish (0)

No personal call yet on MBAI.

Potential upside factors

  • +Growth opportunities may come from revenue expansion, margin improvement, new products, market-share gains, and stronger cash flow.
  • +Hardware-agnostic AI platform architecture.
  • +Proven enterprise-scale deployments.

Potential downside factors

  • −Key risks may include competition, margin pressure, debt levels, valuation risk, and changes in demand within the Biotechnology industry.
  • −Operational risks associated with scaling commercial deployments.
  • −Dependence on successful integration of merger activities.
  • −Negative free cash flow may increase the need for outside financing and dilution.

These research factors come from saved company research and financial data, not community votes. They are starting points to verify against filings, not buy or sell recommendations.

Create a free account to make a call.

Scores

Click any score for full breakdown

—

Tap for breakdown →

—

Debt Cost1156.3%
Debt Reduction YoY88.2%
Debt / Equity0.00x

Tap for breakdown →

—

Revenue YoY—
Revenue CAGR—
Net Margin—

Tap for breakdown →

—

Asset Growth YoY1885.7%
Liquidation/Share$3.86
Net Assets/MCap3.65x

Tap for breakdown →

—

Earnings Yield202.5%
Buyback Yield0.0%
Debt Cost1156.3%

Tap for breakdown →

—

ROIC-68.8%
ROE120.5%
ROA55.3%

Tap for breakdown →

—

EPS Growth—
FCF/Share Growth—
Rev/Share Growth—

Tap for breakdown →

—

Intrinsic Value—
Value Reference—
MOS—

Tap for breakdown →

—

Revenue—
Moat—
Valuation—

Tap for breakdown →

—

MOS %—
Value Reference—
Deep Discount Reference—

Tap for breakdown →

—

Interest Coverage-12.8x
ROIC-68.8%
FCF Yield-2.3%

Tap for breakdown →

—

Financial—
Valuation—
Debt—

Tap for breakdown →

—

Survival Years4.8 yrs
Current Ratio0.05x
FCF Margin—

Tap for breakdown →

Was this stock page easy to understand?

One click helps us improve the research experience. This is not tied to an investment decision.

Score Changes

Score changes will appear once more historical records are available.

Price vs. Value

Valuation unavailable

Current Price

$2.04

Model Intrinsic Value

—

Difference

—

Margin of Safety

—

Value Reference: —
Deep Discount Reference: —

Intrinsic value is not currently available for this stock, so valuation can't be calculated.

Financial Charts

Revenue

20212022202320242025$0$1$2$3$4

Additional Metrics

Operating Cash Flow

20212022202320242025-$20M-$15M-$10M-$5M$0

Total Debt

20212022202320242025$0$300000$600000$900000$1M

Total Assets

20212022202320242025$0$15M$30M$45M$60M

Net Margin %

No data
Monetary values in USD. Share counts in raw units.

Free includes 3 annual periods plus available TTM; Premium includes up to 10 annual periods. History depends on available company filings. Swipe the table horizontally to see older periods. A dash means unavailable, not zero.

Line Item20252024202320222021
Revenue$0.00$0.00$0.00········
Cost of Revenue$0.00$0.00$0.00········
Gross Profit$0.00$0.00$0.00········
Research & Development$0.00$0.00$8.3M········
SG&A Expenses$2.3M$9.3M$9.5M········
Operating Expenses$2.4M$25.9M$19.3M········
EBITDA$4.4M-$25.0M-$17.3M········
Operating Income-$2.4M-$25.9M-$19.3M········
Interest Expense$185K$9K$13K········
Income Before Tax$4.1M-$25.1M-$17.6M········
Income Tax Expense$0.00$0.00$0.00········
Net Income$4.1M-$25.1M-$17.6M········
Basic EPS$4.62$-30.10$-21.00········
Basic Shares890K836K836K········
Diluted Shares890K836K836K········
Upgrade to Premium for up to 10 annual periods, where available.
Upgrade to Premium

Earnings Summary

Estimated earnings date:Mar 3, 2027
Estimated EPS: -$0.01Estimated revenue: $3.7M
Dec 31, 2025FYFY2025

Revenue

$0

Estimate unavailable.

Revenue Beat/Miss

Not available (no estimate stored)

EPS

$4.62

Estimate unavailable.

EPS Beat/Miss

Not available (no estimate stored)

Debt Change

-88.2%

Cash Change

Not available

Margin Change

Not available

Debt and cash show percentage changes versus the comparison period; margin shows the change in percentage points (pp). These are company-wide changes, not per-share amounts.

Financial Changes Since Prior Period

What Improved

  • Debt reduced

Potential Score Impact

Positive indicators included debt levels. Pressure indicators included EPS growth. These factors may support or pressure the Revenue, Management, Financial, and Debt categories; this summary does not claim that the stored scores changed.

Stored Earnings Analysis

EPS declined 115.3%. Total debt declined 88.2%.

Earnings-Call Transcript

Earnings-call transcript analysis is not currently available.

These results may influence future scores when the next evaluation is completed.

Earnings data: 301 days ago · Stale

Insider Activity

Guru / Smart Money

Guru Score

Smart Money

Number of Gurus

Total Guru Value

Avg Portfolio Weight

Largest Holder

Largest Holder %

New Positions

Increased Positions

Reduced Positions

Exited Positions

Net Guru Sentiment

Loading data...

Short Interest

Government disclosed trading activity is available on the Smart Money directory. Filings may be delayed and may not represent complete current holdings.

Dividend History

Dividend data is not available yet. Missing data does not mean this company pays no dividend.

Conservative Projected Values

3 Years

$———.——

Premium

5 Years

$———.——

Premium

10 Years

$———.——

Premium

Conservative Projection Rate

——%

Premium

Conservative Projected Values — price projections derived from actual 10-year adjusted historical returns, conservatively adjusted and capped at 8% annually. These are distinct from the Outperformance Model Score and WallStreetScore.

Conservative Projected Values

Premium unlocks the 3-year, 5-year, and 10-year conservative projected values with full calculation breakdowns based on actual historical returns.

Start 7-Day Free Trial

Historical Outperformance Record

Premium includes stored forecasts and any available evaluated results. Completed results, win rates and calibrated probabilities are shown only when supported records exist; access does not create historical outcomes.

Start 7-Day Free Trial

Historical Trends

5 historical records
Jul 24, 26Sep 19, 26Oct 1, 26Oct 5, 26Oct 23, 260255075100

Historical Score Chart

3 of 5 records shown
3 historical score records are shown. Start your seven-day free trial to unlock 2 more records and the complete score history.Start Free Trial

Wall Street Score

Oct 1, 26Oct 5, 26Oct 23, 260255075100

Debt Score

Oct 1, 26Oct 5, 26Oct 23, 260255075100

Revenue Score

No data

Asset Score

Oct 1, 26Oct 5, 26Oct 23, 260255075100

Capital Score

Oct 1, 26Oct 5, 26Oct 23, 260255075100

Management Score

Oct 1, 26Oct 5, 26Oct 23, 260255075100

Moat Score

Oct 1, 26Oct 5, 26Oct 23, 260255075100

Valuation Score

Oct 1, 26Oct 5, 26Oct 23, 260255075100

Buffett Score

No data

Intrinsic Value

No data

Value Reference

No data

Margin of Safety %

No data

Related Companies

Biotechnology

AUPH

Aurinia Pharmaceuticals Inc.

84Strong
$16.74View

CGEN

Compugen Ltd.

76Strong
$1.94View

ACAD

Acadia Pharmaceuticals Inc.

73Strong
$20.44View

ORMP

Oramed Pharmaceuticals Inc.

72Strong
$4.07View

HRMY

Harmony Biosciences Holdings, Inc.

71Strong
$36.03View

CPRX

Catalyst Pharmaceuticals, Inc.

69Fair
$31.49View

News

Rumor Mill · MBAI

Corporate developments & opportunities

Explore market →

No reviewed developments match this filter.

Evidence credibility is not a forecast of stock performance. Rumor Mill is separate from the WSS score.

Related Stock Research

Continue researching this company with related Wall Street Score rankings and investing guides.

Highest Wall Street Score stocksStocks under $10Best healthcare stocksHow Wall Street Score worksHow to analyze a stockUnderstanding financial healthIntrinsic value guide

Score Alerts

Premium unlocks alerts when a score rises, falls, or reaches your target price.

Start 7-Day Free Trial

Portfolio Score

Premium unlocks portfolio scoring, strongest and weakest holdings, and overall margin of safety.

Start 7-Day Free Trial